264 related articles for article (PubMed ID: 32388482)
1. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.
Lu C; Guo C; Chen H; Zhang H; Zhi L; Lv T; Li M; Niu Z; Lu P; Zhu W
Mol Immunol; 2020 May; 122():200-206. PubMed ID: 32388482
[TBL] [Abstract][Full Text] [Related]
2. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell.
Li M; Zhi L; Yin M; Guo C; Zhang H; Lu C; Zhu W
Biochem Biophys Res Commun; 2020 Mar; 523(3):745-752. PubMed ID: 31952789
[TBL] [Abstract][Full Text] [Related]
4. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
[TBL] [Abstract][Full Text] [Related]
5. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
6. Novaferon gene modification promotes NK92 cell anti-tumor activity.
Zhang W; Yu B; Meng Q; Pu L; Liu B; Li F
Int Immunopharmacol; 2023 Sep; 122():110613. PubMed ID: 37421776
[TBL] [Abstract][Full Text] [Related]
7. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo.
Park E; Mun HJ; Seo E; Hwang S; Lee JH; Song S; Sung H; Kim HY; Kwon MJ
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275419
[TBL] [Abstract][Full Text] [Related]
8. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report.
Zhang X; Guo Y; Ji Y; Gao Y; Zhang M; Liu Y; Zhu W; Lu P
Cell Transplant; 2022; 31():9636897221094244. PubMed ID: 35506155
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.
Luo H; Wu X; Sun R; Su J; Wang Y; Dong Y; Shi B; Sun Y; Jiang H; Li Z
Front Oncol; 2019; 9():1448. PubMed ID: 31921693
[TBL] [Abstract][Full Text] [Related]
12. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells.
Liu H; Yang B; Sun T; Lin L; Hu Y; Deng M; Yang J; Liu T; Li J; Sun S; Jiao S
Oncol Rep; 2015 Jan; 33(1):95-102. PubMed ID: 25333815
[TBL] [Abstract][Full Text] [Related]
13. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
14. An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Zhao H; Zhou Z; Li G; Liu G; Lin S; Chen W; Xiong S
Cytotechnology; 2021 Aug; 73(4):539-553. PubMed ID: 34349345
[TBL] [Abstract][Full Text] [Related]
15. The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.
Wang X; Qiu W; Liu H; He M; He W; Li Z; Wu Z; Xu X; Chen P
Cancer Biol Med; 2023 Sep; 20(9):662-81. PubMed ID: 37731205
[TBL] [Abstract][Full Text] [Related]
16. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
Qu Y; Bi JZ
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
[No Abstract] [Full Text] [Related]
17. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
Althaus J; Nilius-Eliliwi V; Maghnouj A; Döring S; Schroers R; Hudecek M; Hahn SA; Mika T
Cancer Immunol Immunother; 2023 Aug; 72(8):2573-2583. PubMed ID: 37052701
[TBL] [Abstract][Full Text] [Related]
18. A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets.
Kang HY; Lee SY; Kim HM; Lee SU; Lee H; Cho MY; Oh SC; Kim SM; Park HS; Han EH; Kim SE; Kim H; Yoon SR; Doh J; Chung J; Hong KS; Choi I; Kim TD
Front Immunol; 2022; 13():1089369. PubMed ID: 36713381
[TBL] [Abstract][Full Text] [Related]
19. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
